Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of NLX P101 in patients with Parkinson's disease.

Trial Profile

Phase III trial of NLX P101 in patients with Parkinson's disease.

Planning
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2011

At a glance

  • Drugs NLX P101 (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Neurologix
  • Most Recent Events

    • 16 Mar 2011 Trial is still being planned.
    • 07 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top